1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 17:1726–1733. 2006.
Article
2. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA. 298:629–637. 2007.
Article
3. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 15:767778. 2004.
Article
4. Colón-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA. 296:2968–2969. 2006.
5. Ha YC, Kim KW, Kim SH, Park YG. Bone biopsy of atypical subtrochanteric fracture in patient with prolonged bisphosphonate therapy: a case report. Korean J Bone Metab. 18:131–135. 2011.
6. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 25:2267–2294. 2010.
Article
7. Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J. 99:295–302. 2017.
8. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 29:1–23. 2014.
Article
9. Lee YK, Yoon BH, Koo KH. Epidemiology and clinical features of atypical femoral fractures. J Korean Orthop Assoc. 48:175–179. 2013.
Article
10. Schilcher J. High revision rate but good healing capacity of atypical femoral fractures. A comparison with common shaft fractures. Injury. 46:2468–2473. 2015.
Article
11. Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res. 470:2295–2301. 2012.
Article
12. Whelan DB, Bhandari M, McKee MD, et al. Interobserver and intraobserver variation in the assessment of the healing of tibial fractures after intramedullary fixation. J Bone Joint Surg Br. 84:15–18. 2002.
Article
13. Lim HS, Kim CK, Park YS, Moon YW, Lim SJ, Kim SM. Factors associated with increased healing time in complete femoral fractures after longterm bisphosphonate therapy. J Bone Joint Surg Am. 98:1978–1987. 2016.
Article
14. Gómez-Barrena E, Rosset P, Lozano D, Stanovici J, Ermthaller C, Gerbhard F. Bone fracture healing: cell therapy in delayed unions and nonunions. Bone. 70:93–101. 2015.
Article
15. Abrahamsen B, Eiken P, Eastell R, et al. Cumulative alendronate dose and the longterm absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 95:5258–5265. 2010.
Article
16. Abrahamsen B, Einhorn TA. Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. Bone. 50:1196–1200. 2012.
Article
17. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 90:1294–1301. 2005.
Article
18. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 22:346–350. 2008.
Article
19. Winquist RA, Hansen ST Jr, Clawson DK. Closed intramedullary nailing of femoral fractures. A report of five hundred and twenty cases. J Bone Joint Surg Am. 66:529–539. 1984.
Article
20. Kempf I, Grosse A, Rigaut P. The treatment of noninfected pseudarthrosis of the femur and tibia with locked intramedullary nailing. Clin Orthop Relat Res. 212:142–154. 1986.
Article
21. Webb LX, Winquist RA, Hansen ST. Intramedullary nailing and reaming for delayed union or nonunion of the femoral shaft. A report of 105 consecutive cases. Clin Orthop Relat Res. 212:133–141. 1986.
22. Wu CC, Chen WJ. Treatment of femoral shaft aseptic nonunions: comparison between closed and open bone-grafting techniques. J Trauma. 43:112–116. 1997.
23. Canadian Orthopaedic Trauma Society. Nonunion following intramedullary nailing of the femur with and without reaming. Results of a multicenter randomized clinical trial. J Bone Joint Surg Am. 85:2093–2096. 2003.
24. Wolinsky PR, McCarty E, Shyr Y, Johnson K. Reamed intramedullary nailing of the femur: 551 cases. J Trauma. 46:392–399. 1999.
25. Sims SH. Subtrochanteric femur fractures. Orthop Clin North Am. 33:113–126. viii,. 2002.
26. Vanderschot P, Vanderspeeten K, Verheyen L, Broos P. A review on 161 subtrochanteric fractures: risk factors influencing outcome: age, fracture pattern and fracture level. Unfallchirurg. 98:265–271. 1995.
27. Garland DE, Rieser TV, Singer DI. Treatment of femoral shaft fractures associated with acute spinal cord injuries. Clin Orthop Relat Res. 197:191–195. 1985.
Article
28. Teo BJ, Koh JS, Goh SK, Png MA, Chua DT, Howe TS. Postoperative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Joint J. 96:658–664. 2014.
Article
29. Fogagnolo F, Kfuri M Jr, Paccola CA. Intramedullary fixation of pertrochanteric hip fractures with the short AO-ASIF proximal femoral nail. Arch Orthop Trauma Surg. 124:31–37. 2004.
Article
30. Kwon BT, Kwon SH. Prediction of type of proximal femur fracture by analysis of serum makers. Osteoporosis. 13:31–35. 2015.
31. Lee HS, Lee CS, Jang JS, Lee JD, Um SM. Changes of serum alkaline phosphatase and osteocalcin during fracture healing. J Korean Orthop Assoc. 37:411–415. 2002.
Article
32. Leung KS, Fung KP, Sher AH, Li CK, Lee KM. Plasma bone-specific alkaline phosphatase as an indicator of osteoblastic activity. J Bone Joint Surg Br. 75:288–292. 1993.
Article